Zhijun Zhang is the Vice President, Chief Scientific Officer, and the Co-founder of Zhimeng Biopharma. Having worked in both pharmaceutical industries and academia, Dr. Zhang brought in deep understanding of disease biology and rich experience in drug discovery and development. Prior to starting Zhimeng Biopharma, Dr. Zhang was the Head of Virus Research at Sanofi's Asia-Pacific R&D Hub for 7+ years, overseeing all antiviral research activities of the region of the company.


Before Joining Sanofi, Dr. Zhang was an Associate Professor at Oklahoma University Health Science Center (OKHSC), USA. In that position, he conducted preclinical and clinical research on multiple anti-virus and anti-bacterial products.


Before joining the faculty of OUHSC, Dr. Zhang was at Valeant Pharmaceutical Internationals (California, USA) with increasing responsibilities in antiviral discovery. Dr. Zhang was responsible for the discovery of Lesinurad (Zurampic) that initially was developed for treatment of HIV and later was repositioned to treat hyperuricemia associated with Gout.


Dr. Zhang has authored 20 scientific publications and numerous patents. Dr. Zhang obtained his Ph.D. in Microbiology and received his post-doctoral training both at the University of Alabama at Birmingham, USA.